Viewing nowCombinationGlyan Duo Tablet 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin Amorphous 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.

MFDS item code 202500926 · Approved 2025.04.17 · Insurance code 643705600
Improves blood glucose control in adults with type 2 diabetes mellitus
This drug is used as a treatment to help adults with type 2 diabetes control their blood sugar levels by combining empagliflozin and metformin. It is especially effective when administered as an adjunct to dietary control and exercise therapy, effectively improving blood sugar levels. It may also be used in patients with type 2 diabetes who have cardiovascular disease, but it is important to consider the risks of cardiovascular events as per expert recommendations. Therefore, this drug helps control blood sugar and shows positive effects in diabetes treatment.
The recommended dose of this medicine is 1 tablet twice daily. The dose is determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose of this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin to this medicine should receive their current doses of empagliflozin and metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you forget to take this medicine, take it as soon as you remember. However, do not take double the dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given with this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Careful Administration, item 1)). If renal function declines to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication may cause a dangerous condition known as severe lactic acidosis, so precautions are necessary particularly in patients with impaired kidney function or weak heart or liver function. When used with insulin or sulfonylureas, hypoglycemia may occur, so blood sugar changes should be closely monitored while using together. This drug should not be used in patients with moderate to severe renal impairment or those in situations that may lead to acute kidney injury, and should also be avoided during acute illnesses such as dehydration, severe infections, or acute myocardial infarction. Additionally, it should not be used in patients with type 1 diabetes, a history of diabetic ketoacidosis, unstable or acute heart failure, or women who are pregnant or breastfeeding. Before and after procedures using iodinated contrast agents, this drug should be discontinued due to the risk of worsening kidney function and lactic acidosis, and it should only be resumed after ensuring normal kidney function. Regular kidney function tests should be conducted during treatment, especially in the elderly or those with slightly decreased kidney function who may require more frequent assessments. Caution should be exercised in patients at risk of fluid loss or those prone to dehydration due to gastrointestinal disturbances; in such cases, temporary discontinuation of medication may be necessary. This drug may cause side effects such as hypoglycemia, urinary infections, genital infections, increased urination, gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.), so consultation with healthcare professionals should occur upon symptom onset. It is safest for women who are pregnant or may become pregnant and nursing mothers not to use this medication. If breastfeeding, it should be discontinued. Safety and efficacy in pediatric patients have not been established; thus, children under 18 years of age should not use this medication. Elderly patients are at higher risk for decreased renal function and should have their dosage adjusted and renal function regularly monitored. In cases of overdose, appropriate treatments such as hemodialysis may be necessary, and immediate medical attention should be sought if symptoms appear.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container as it may be sensitive to air or moisture. The recommended storage temperature is at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication and prevents it from deteriorating.
Biconvex oval film-coated tablets with a dark brownish-purple hue
30 tablets/box [(6 tablets/PTP × 5)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin Amorphous 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationEmpagliflozin Amorphous 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Empagliflozin Amorphous 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationEmpagliflozin Amorphous 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Empagliflozin Amorphous 25mg
Tablet · Prescription medication · Combination
Aprogen Pharmaceuticals Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Empagliflozin Amorphous 10mg
Tablet · Prescription medication · Combination
Aprogen Biosystems, Co., Ltd.
CombinationEmpagliflozin Amorphous 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationEmpagliflozin Amorphous 25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.